<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sousonis, V.</style></author><author><style face="normal" font="default" size="100%">Sfakianaki, T.</style></author><author><style face="normal" font="default" size="100%">Ntalianis, A.</style></author><author><style face="normal" font="default" size="100%">Nanas, I.</style></author><author><style face="normal" font="default" size="100%">Kontogiannis, C</style></author><author><style face="normal" font="default" size="100%">Aravantinos, D.</style></author><author><style face="normal" font="default" size="100%">Kapelios, C.</style></author><author><style face="normal" font="default" size="100%">Katsaros, L.</style></author><author><style face="normal" font="default" size="100%">Nana, M.</style></author><author><style face="normal" font="default" size="100%">Sampaziotis, D.</style></author><author><style face="normal" font="default" size="100%">Sanoudou, D.</style></author><author><style face="normal" font="default" size="100%">Papalois, A</style></author><author><style face="normal" font="default" size="100%">Malliaras, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Intracoronary Administration of Allogeneic Cardiosphere-Derived Cells Immediately Prior to Reperfusion in Pigs With Acute Myocardial Infarction Reduces Infarct Size and Attenuates Adverse Cardiac Remodeling</style></title><secondary-title><style face="normal" font="default" size="100%">J Cardiovasc Pharmacol TherJ Cardiovasc Pharmacol TherJ Cardiovasc Pharmacol Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cardiovascular pharmacology and therapeutics</style></alt-title><short-title><style face="normal" font="default" size="100%">Journal of cardiovascular pharmacology and therapeuticsJournal of cardiovascular pharmacology and therapeutics</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Ventricular Function, Left</style></keyword><keyword><style  face="normal" font="default" size="100%">*Ventricular Remodeling</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Fibrosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocardial Infarction/pathology/physiopathology/*surgery</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocardial Reperfusion Injury/pathology/physiopathology/*surgery</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocardium/*pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocytes, Cardiac/*transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Sus scrofa</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplantation, Homologous</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">26</style></volume><pages><style face="normal" font="default" size="100%">88-99</style></pages><isbn><style face="normal" font="default" size="100%">1940-4034 (Electronic)1074-2484 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Allogeneic cardiosphere-derived cells (CDCs) exert cardioprotective effects when administered intracoronarily after reperfusion in animal models of acute myocardial infarction (AMI). The &quot;no-reflow&quot; phenomenon develops rapidly post-reperfusion and may undermine the efficacy of cell therapy, due to poor cell delivery in areas of microvascular obstruction (MVO). We hypothesized that CDC-induced cardioprotection would be enhanced by cell administration prior to reperfusion, when microvasculature is still relatively intact, to facilitate widespread cell delivery within the ischemic area. METHODS AND RESULTS: We studied 81 farm pigs; 55 completed the specified protocols. A dose-optimization study in infarcted pigs demonstrated that the doses of 5 million and 10 million CDCs are the maximum safe doses that can be administered intracoronarily at 5 minutes prior to and at 5 minutes post-reperfusion, respectively, without aggravating MVO. Quantification of acute cell retention by polymerase chain reaction demonstrated that cell delivery prior to reperfusion resulted in higher cardiac cell retention compared to delivery post-reperfusion. We then performed a randomized, placebo-controlled study to assess the long-term efficacy of intracoronary infusion of 5 million allogeneic CDCs, delivered at 5 minutes prior to reperfusion, in a porcine model of AMI. The CDC therapy resulted in decreased scar size, improved regional systolic function, and attenuation of adverse cardiac remodeling (manifested as preserved global systolic function, preserved end-systolic volume, and decreased interstitial fibrosis) compared to placebo at 30 days post-MI. CONCLUSIONS: Dose-optimized intracoronary infusion of allogeneic CDCs prior to reperfusion in a porcine model of AMI is feasible, safe and confers long-term benefits.</style></abstract><accession-num><style face="normal" font="default" size="100%">32677460</style></accession-num><notes><style face="normal" font="default" size="100%">Sousonis, VasileiosSfakianaki, TitikaNtalianis, ArgiriosNanas, IoannisKontogiannis, ChristosAravantinos, DionysiosKapelios, ChrisKatsaros, LamprosNana, MariaSampaziotis, DimitriosSanoudou, DespinaPapalois, ApostolosMalliaras, KonstantinosengRandomized Controlled Trial, VeterinaryResearch Support, Non-U.S. Gov't2020/07/18 06:00J Cardiovasc Pharmacol Ther. 2021 Jan;26(1):88-99. doi: 10.1177/1074248420941672. Epub 2020 Jul 17.</style></notes><auth-address><style face="normal" font="default" size="100%">Third Department of Cardiology, University of Athens School of Medicine, Athens, Greece.Center for New Biotechnologies and Precision Medicine, University of Athens School of Medicine, Athens, Greece.Department of Pathology, Evangelismos Hospital, Athens, Greece.Fouth Department of Internal Medicine, Clinical Genomics and Pharmacogenomics Unit, Attikon Hospital, University of Athens School of Medicine, Athens, Greece.Experimental Educational and Research Center, ELPEN Pharmaceuticals, Athens, Greece.</style></auth-address></record></records></xml>